Trial Profile
A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) With Temsirolimus in Children With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma (DIPG)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary) ; Vorinostat (Primary)
- Indications Diffuse intrinsic pontine glioma; Glioma
- Focus Adverse reactions
- 13 Feb 2024 Planned End Date changed from 31 Oct 2023 to 31 Oct 2024.
- 13 Feb 2024 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2024.
- 20 Jan 2023 Planned End Date changed from 31 Oct 2022 to 31 Oct 2023.